Cytek BioSciences (CTKB) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Cytek BioSciences (CTKB) do?
Cytek BioSciences Inc (CTKB) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells spectral flow cytometers and cell sorters that identify cell types using light emission profiles. Uses full spectrum profiling to capture the entire light signature of cells for biological research. It is worth $826.55M on the market and sold $207.68M over the last year.
- Market cap
- $826.55M
- P/E ratio
- None (reported a loss)
- Annual sales
- $207.68M
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 19, 2026
Brands and businesses behind CTKB
- Cytek Aurora: Sells advanced spectral flow cytometer systems and cell sorting units to pharmaceutical and academic laboratories worldwide.
- Amnis: Generates revenue by selling high-speed imaging flow cytometers that capture microscopic images of cells in suspension.
- Guava: Sells compact, microcapillary flow cytometers and associated consumable assays for routine cell counting and health monitoring.
- Northern Lights: Earns revenue through mid-range spectral cytometers tailored for standard laboratory diagnostics and basic research applications.
CTKB’s flags, in plain English
Each flag is a number from Cytek BioSciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.
Stupid Cash
Can pay this year's bills 4.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 10% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Still Climbing
Sales up 16.8% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Burning Cash
Losing money, profit margin of -39.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about CTKB
How big is Cytek BioSciences?
Cytek BioSciences’ market cap is $826.55M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $207.68M: what customers paid the company over the last year, before any costs.
What is CTKB’s P/E ratio?
CTKB has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with CTKB?
A large portion of revenue depends on academic institutions and biotechnology firms that cut equipment spending during funding droughts. That is one risk on Cytek BioSciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Cytek BioSciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CTKB’s filings on SEC.gov. The Margin Monkey is research, not advice.
